Przybysz Sandra, Łojko-Dankowska Anna, Rakoczy Magdalena, Marcinkowska-Swojak Małgorzata, Zeńczak Michał, Gwóźdź-Bąk Kinga, Handschuh Luiza, Lewandowski Krzysztof
Department of Hematology and Bone Transplantation, University of Medical Sciences, Poznań, Poland.
Students Scientific Society, PUMS, Poznań, Poland.
J Appl Genet. 2025 Aug 9. doi: 10.1007/s13353-025-00999-9.
Atypical chronic lymphocytic leukemia (aCLL) is an indolent lymphoproliferative neoplasm derived from CD19-positive and CD5 or CD23-negative B cells. This paper presents the results of whole genome sequencing (WGS) of lymphoma cells collected from a 29-year-old woman initially diagnosed with aCLL and successfully treated with fludarabine, cyclophosphamide, and rituximab. Eight years later, due to disease progression, she was treated with ibrutinib. After 5 months, her status suddenly deteriorated. PET-CT results suggested Richter transformation (RT). Histopathological examination of nodal lesions confirmed the diagnosis of Diffuse Large B Cell Lymphoma (DLBCL). Finally, the patient was successfully treated with DHAP-R and alloHSCT. WGS of lymphoma cells revealed the presence of pathogenic (COL11A1, MGME1) and likely pathogenic variants (ZMYM3, ALG6, UBA5, and ATG7). Out of these genes, only ZMYM3 is recurrently mutated in B-cell chronic lymphocytic leukemia (B-CLL). The presence of the other lesions requires further studies and indicates the complex molecular background of aCLL transformation to DLBCL. Therefore, the whole-genome variant assessment is worth considering for introduction into a routine procedure at the time of B-CLL diagnosis, especially when RT is suspected.
非典型慢性淋巴细胞白血病(aCLL)是一种惰性淋巴细胞增殖性肿瘤,起源于CD19阳性、CD5或CD23阴性的B细胞。本文介绍了对一名29岁女性淋巴瘤细胞进行全基因组测序(WGS)的结果,该女性最初被诊断为aCLL,并成功接受了氟达拉滨、环磷酰胺和利妥昔单抗治疗。八年后,由于疾病进展,她接受了伊布替尼治疗。5个月后,她的病情突然恶化。PET-CT结果提示里氏转化(RT)。淋巴结病变的组织病理学检查确诊为弥漫性大B细胞淋巴瘤(DLBCL)。最后,患者成功接受了DHAP-R和异基因造血干细胞移植(alloHSCT)治疗。淋巴瘤细胞的WGS显示存在致病性(COL11A1、MGME1)和可能致病性变异(ZMYM3、ALG6、UBA5和ATG7)。在这些基因中,只有ZMYM3在B细胞慢性淋巴细胞白血病(B-CLL)中反复发生突变。其他病变的存在需要进一步研究,并表明aCLL转化为DLBCL的分子背景复杂。因此,在B-CLL诊断时,尤其是怀疑有RT时,全基因组变异评估值得考虑引入常规程序。